Illumina (NASDAQ:ILMN) Director Sells $32,758,501.85 in Stock

Illumina, Inc. (NASDAQ:ILMN) Director Keith Meister sold 225,067 shares of the company’s stock in a transaction dated Wednesday, May 13th. The shares were sold at an average price of $145.55, for a total transaction of $32,758,501.85. Following the sale, the director directly owned 3,604,441 shares in the company, valued at approximately $524,626,387.55. This trade represents a 5.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Illumina Price Performance

NASDAQ ILMN opened at $142.54 on Friday. The company has a market cap of $21.57 billion, a PE ratio of 25.92, a price-to-earnings-growth ratio of 2.36 and a beta of 1.42. Illumina, Inc. has a 52 week low of $78.55 and a 52 week high of $155.53. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56. The firm’s 50-day simple moving average is $128.58 and its two-hundred day simple moving average is $129.52.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The firm had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same period in the prior year, the firm posted $0.97 earnings per share. The company’s revenue for the quarter was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Research analysts predict that Illumina, Inc. will post 5.2 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on ILMN shares. JPMorgan Chase & Co. increased their price target on shares of Illumina from $120.00 to $125.00 and gave the stock a “neutral” rating in a report on Friday, May 1st. Stifel Nicolaus increased their price target on shares of Illumina from $135.00 to $155.00 and gave the stock a “buy” rating in a report on Tuesday, January 20th. Barclays increased their price target on shares of Illumina from $110.00 to $122.00 and gave the stock an “underweight” rating in a report on Friday, May 1st. Piper Sandler lowered their price target on shares of Illumina from $195.00 to $170.00 and set an “overweight” rating on the stock in a report on Monday, February 9th. Finally, Citigroup increased their price target on shares of Illumina from $80.00 to $95.00 and gave the stock a “sell” rating in a report on Monday, May 4th. Seven equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Illumina has an average rating of “Hold” and a consensus price target of $137.75.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Capital World Investors increased its position in shares of Illumina by 0.6% in the fourth quarter. Capital World Investors now owns 20,101,173 shares of the life sciences company’s stock worth $2,636,483,000 after purchasing an additional 124,323 shares during the last quarter. State Street Corp increased its position in shares of Illumina by 3.2% in the fourth quarter. State Street Corp now owns 6,190,114 shares of the life sciences company’s stock worth $811,895,000 after purchasing an additional 190,324 shares during the last quarter. WCM Investment Management LLC increased its position in shares of Illumina by 45.5% in the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock worth $715,579,000 after purchasing an additional 1,851,848 shares during the last quarter. AQR Capital Management LLC increased its position in shares of Illumina by 30.3% in the fourth quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock worth $580,531,000 after purchasing an additional 1,028,099 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Illumina by 4.8% in the fourth quarter. Geode Capital Management LLC now owns 2,869,047 shares of the life sciences company’s stock worth $375,260,000 after purchasing an additional 130,139 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.